Skye Bioscience Inc

Research Skye Bioscience Inc (SKYE) on Bullrun: market cap USD 23.56M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerSKYE
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 23.56M
• Financial periodFY2025
• Net income-USD 55.92M
• Free cash flow-USD 43.07M

Valuation Snapshot

latest market cap is USD 23.56M.

About Skye Bioscience Inc

Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021.

Frequently asked questions

What is Skye Bioscience Inc's market cap?

Skye Bioscience Inc's market capitalization is USD 23.56M.

What does Skye Bioscience Inc do?

Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases.